Children and caregiver proxy quality of life from peanut oral immunotherapy trials.

"CONFLICT OF INTEREST Audrey Dunn Galvin reports grants or contracts from DBV Technologies, WAO, and EAACI and payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing, or educational events by DBV Technologies, Nutritics, and Nutricia. Andrea Vereda is an employee of Aimmune Therapeutics, a Nestlé Health Science company. Pablo Rodríguez del Río reports speaker fees from Aimmune Therapeutics, a Nestlé Health Science company. Antonella Muraro reports speaker fees from Aimmune Therapeutics, a Nestlé Health Science company, DBV Technologies, Viatris‐Mylan, ALK, Nestlé Health Science, Nestlé Purina, Novartis, and Nutricia Research; advisory board for Novartis, Regeneron, Aimmune Therapeutics, a Nestlé Health Science company, DBV Technologies, and Viatris; and grants from Aimmune Therapeutics, a Nestlé Health Science company, and Sanofi. Carla Jones reports nonpersonal sponsorship for Allergy UK Primary Care Masterclass for HCPs in 2018 and 2019, as well as nonpersonal sponsorship for Allergy UK webinar for HCPs and article in Allergy Today 2021 by Aimmune Therapeutics, a Nestlé Health Science company; nonpersonal sponsorship for Allergy UK for a survey and report 2018 and nonpersonal sponsorship for Allergy UK for an abstract, poster, and round table report 2019 by DBV; fees for Allergy UK to attend European Insights Workshop October 2018 – reading survey, review program, attend workshop, reading and meeting attendance October 2019, and review of educational handbooks and videos 2020 by Aimmune Therapeutics, a Nestlé Health Science company; nonpersonal sponsorship for Allergy UK for review and dissemination of vignette study 2020 by DBV Technologies; and a colleague was supported to attend PAAM 2019 as presenting a poster by DBV Technologies. Robert Ryan is an employee of Aimmune Therapeutics, a Nestlé Health Science company. David Norval is an employee of Aimmune Therapeutics, a Nestlé Health Science company. Jennifer Jobrack was a previous consultant to Aimmune Therapeutics, a Nestlé Health Science company, and spoke at ACAAI in February 2020. Aikaterini Anagnostou reports grants from Aimmune Therapeutics, a Nestlé Health Science company, during the conduct of the study; personal fees from DBV Technologies; grants and personal fees from FARE; and personal fees from ALK outside the submitted work. Julie Wang reports research support to her institution from Aimmune Therapeutics, a Nestlé Health Science company, DBV Technologies, Genentech, and Regeneron; support for attending Joint Task Force meetings for ACAAI; payments received from ALK‐Abello for participation on a data safety monitoring board; payments received from Jubilant HollisterStier for participation on an advisory board; and unpaid AAP Chair of the Executive Committee of the Section on Allergy and Immunology, as well as unpaid AAAAI Chair of the Anaphylaxis Dermatitis Drug Allergy Interest Section."

"The authors wish to acknowledge the ARC003 (PALISADE), ARC004, ARC007 (RAMSES), ARC010 (ARTEMIS), and ARC011 Research Groups, as well as the investigative center trial staff, the trial participants, and their families. The authors also wish to thank Cengiz Han Acikel, Sahin Hacer, and Ralph Mösges. Medical writing/editorial support was provided by Stephanie Phan, PharmD, and Cheryl Casterline, MA (Peloton Advantage, LLC, and OPEN Health Company, Parsippany, NJ), and funded by the study sponsor. This study was sponsored by Aimmune Therapeutics, a Nestlé Health Science company."